AI-generated · cited to primary sources · not investment advice
Marksans Pharma (524404) May 2025 Filing Analysis
Does management do what it says?
Q1 FY26 R&D spending was exactly 2% of consolidated revenue, aligning with the upper end of the guided range. (3 met across 3 tracked commitments)
“Moving on, we do expect the R&D expenditure to remain between, say, 1.9% to 2% on a year-on-year basis.”
See the full cited Management analysis of Marksans Pharma
How durable is the business?
The company is aggressively expanding its product pipeline with 58 SKUs commercialized during the year and 79 more products in the pipeline. (2 expanding)
“And during the year, we managed to commercialize 58 SKUs and have about 79 more products in the pipeline.”
The OTC segment has significantly expanded its dominance, now accounting for 78.8% of total revenue, driven by a 28% YoY growth and crossing the INR 2,000 cr milestone. (3 expanding, 1 contracting, 1 shifted)
“FY25 OTC Revenue – ₹ 2,066.0 cr 28% YoY... OTC 78.8%”
The US market remains the primary growth engine, growing 34.7% for the full year and 34.1% in Q4, despite a slower cough and cold season in the final quarter. (2 expanding, 2 contracting, 1 stable)
“The U.S. and North America market recorded revenue of Rs. 1,237 crores, up by 34.7% on a year-on-year basis and contributing 47% to our total revenue.”
See the full cited Business Model analysis of Marksans Pharma
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.